News: Optimer Pharmaceuticals Inc (OPTR.OQ)
12.48USD
1 Aug 2013
$-0.03 (-0.24%)
$12.51
$12.64
$12.65
$12.48
558,582
327,918
$16.77
$8.66
Tue, Jul 30 2013
Cubist to pay up to $1.6 billion for two antibiotics makers
- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.
UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers
* Cubist sees the sum of both deals to be accretive in 2015
Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion
- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln
(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)
Cubist bid for Optimer before sale process began: sources
NEW YORK - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
Cubist bid almost $1 bln for Optimer before sale process-sources
NEW YORK, May 15 - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
Optimer shares rise after report names Glaxo, Cubist as potential buyers
- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker.
UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers
* Shares up 18 pct (Adds comments from an analyst, details)
Optimer Pharma exploring sale, shares jump
- Drugmaker Optimer Pharmaceuticals Inc said it was exploring a sale and replaced its chief executive as part of a review of compliance issues, sending its shares up 19 percent.
Optimer Pharma exploring sale, shares jump
- Optimer Pharmaceuticals Inc said it was exploring a possible sale of the company among a full range of alternatives and that Chairman Henry McKinnell would act as chief executive for the duration of the review process.
- Cubist Pharmaceuticals: 2 Promising Deals To Bolster Future Pipeline
- The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio
- Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys
- Coming Soon: Optimer Pharmaceuticals Earnings
- 5 Stocks Poised for Breakouts
- Deadly Bacteria Is A Global Crisis: Brad Spellberg
Press Releases
- Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
- Optimer Pharmaceuticals and AstraZeneca Collaborate to Commercialize Fidaxomicin for Clostridium Difficile Infection in Latin America
- Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
- Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
- Optimer Initiates Phase 3b Clinical Trial of DIFICIDĀ® for the Prevention of Clostridium difficile-Associated Diarrhea in Bone Marrow Transplant Patients
- Optimer Pharmaceuticals to Sell Remaining Ownership in Optimer Biotechnology, Inc. for U.S. $60 Million
- Optimer Introduces Strategic Initiative to Further Facilitate Patient Access to DIFICIDĀ®
- Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
- Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
- CMS Grants New Technology Add-on Payment to DIFICIDĀ® for Treatment of Clostridium difficile-associated Diarrhea

